GNI Group Ltd. provided an update on the subject enrollment in Phase III clinical trial in China of F351 (generic name: Hydronidone) for HBV-induced liver fibrosis conducted by one of main subsidiaries, Beijing Continent Pharmaceuticals Co. Ltd. As of May 19, 2023, Continent has completed the enrollments of 124 subjects, which is 50% of the target enrollment.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,389 JPY | -1.36% | -1.80% | -16.93% |
19/03 | Jefferies Adjusts GNI Group’s Price Target to 4,100 Yen From 3,000 Yen, Keeps at Buy | MT |
14/02 | GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.93% | 780M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- 2160 Stock
- News GNI Group Ltd.
- Beijing Continent Achieves Mid-Point Subject Enrollment for F351 Phase III Clinical Trial in China